GlassScriptPhysician profile
Andrea Colvin
NPI 1053824078
$6,089.94
in general payments reported to CMS, 2019-2025
41 companies · $2,031 in 2025
The $2,031 reported for 2025 was more than what 94% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,011 · 2022: $785 · 2023: $916 · 2024: $1,347 · 2025: $2,031.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,293.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,293.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,172.00 | 2021-2025 | |
| Novo Nordisk INC | $842.05 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $615.39 | 2021-2025 | |
| Amgen INC. | $374.42 | 2022-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $272.11 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Sumitomo Pharma America, INC. | $242.24 | 2023-2025 | Gemtesa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $241.50 | 2021-2025 | Jardiance, Synjardy |
| Bayer Healthcare Pharmaceuticals INC. | $218.77 | 2022-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $213.13 | 2024-2025 | Caplyta |
| Axsome Therapeutics, INC. | $184.04 | 2025 | Auvelity, Symbravo |
| Eisai INC. | $177.48 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $149.31 | 2021-2025 | Airsupra, Farxiga |
| E.R. Squibb & Sons, L.L.C. | $138.95 | 2021-2023 | Eliquis |
| Takeda Pharmaceuticals U.S.A., INC. | $119.85 | 2021-2025 | Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $106.13 | 2022-2025 | Xifaxan |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrea Colvin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.